CClinicalTrials.gg
CompletedNCT01961531Updated Mar 4, 2022Results posted

BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)

An interventional study of Accuboost APBI in Breast Cancer, sponsored by Brown University. Completed at 3 sites in United States. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-03-04.

Sponsored by Brown University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
50 Years and older
Sex
Female
01

Study summary

To evaluate safety of 5 fraction accelerated partial brest irradiation in more convenient 5 fraction schedule.

Read the detailed description

The purpose of this study is to evaluate the rate of early and intermediate toxicity related to accelerated partial breast irradiation (APBI) delivered in a more convenient 5 fraction schedule using non-invasive image-guided breast brachytherapy (NIBB) (AccuBoost System) in women with resected, early stage breast cancer.

Non-invasive image-guided breast brachytherapy (NIBB), using advanced image-guided radiation technology, has the potential to eliminate the disadvantages of the conventional APBI techniques. NIBB facilitates non-invasive partial breast irradiation without the use of catheters or implants. Yet by using breast immobilization and precise image-guidance, it reduces non-target breast tissue within the irradiated field compared with other non-invasive APBI techniques such as 3D-CRT. This has made NIBB an attractive approach to deliver APBI.

We hypothesize that NIBB delivered in 5 treatments will be a more convenient, safe and effective modality to deliver partial breast irradiation.

Anticipated advantages of NIBB protocol treatment include:

  • Convenient treatment schedule
  • Short course can allow for increased patient access to treatment
  • Non-invasive approach
  • Increased accuracy with precise targeting of lumpectomy cavity using advanced imaging
  • Reduced irradiation of non-target breast tissue
  • Reduced skin toxicity
  • No heart or lung radiation exposure
  • Reduced late skin or breast toxicity
  • High rate of good or excellent cosmetic outcome
  • High rate of ipsilateral breast tumor control comparable to other APBI techniques
02

Conditions studied

  • Breast Cancer

Keywords

  • DCIS
  • IDC
  • Invasive breast carcinoma
03

In context

Lead sponsor

Brown University is the lead sponsor of 282 studies on the registry; 42 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. A confirmed histological diagnosis of invasive breast carcinoma or DCIS;
  2. Age greater or equal to 50 years old;
  3. Life expectancy > 6 months;
  4. Treated by breast conserving surgery
  5. Pathologic lymph node negative, which includes (pN0 i-, i+);

    Patients, who are at very low risk for sentinel node involvement and sentinel node biopsy is not performed, are eligible if the treating investigator documents clinically lymph node negative (cN0). These patients include:

    • DCIS
    • Microinvasion only
    • Pure tubular or mucinous histology
    • Patients ≥ 70yo with T1a-T1c; estrogen receptor +
  6. Pathologic tumor size

    1. less than or equal to 2 cm for invasive disease;
    2. less than or equal to 3 cm for DCIS;
  7. Estrogen receptor positive if invasive disease (DCIS can be ER negative)
  8. Negative surgical margins greater than or equal to 2 mm. A margin of \<2mm is acceptable if at natural boundary, i.e. skin or pectoralis fascia.
  9. No lymphovascular invasion;
  10. ECOG performance status of 0-2 (Appendix 1);
  11. Informed consent signed.

Exclusion criteria

Exclusion Criteria:

  1. Known BRCA 1/2 Mutation; (BRCA 1 and 2 testing is not required)
  2. Active lupus or scleraderma;
  3. Pregnancy;
  4. Psychiatric or addictive disorder that would preclude attending follow-up;
  5. Neoadjuvant chemotherapy (adjuvant chemotherapy is permitted);
  6. Suspicious remaining microcalcification on post-surgery mammogram (unless biopsy proven benign);
  7. pN+ on axillary dissection or in the sentinel lymph node biopsy (N0i+ are considered node negative and are not excluded);
  8. Multicentric disease;
  9. Paget's disease of the nipple;
  10. Breast Implants
  11. Distant metastases;
  12. Lumpectomy cavity not well visualized on AccuBoost imaging;
  13. Lumpectomy cavity with 1cm margin (CTV/PTV) not adequately encompassed by any available applicator.
  14. Breast separation with compression > 8cm at time of simulation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Accuboost APBI

    28Gy delivered in 5 daily fractions

    Device: Accuboost APBI

Interventions

  • DeviceAccuboost APBI

    28Gy delivered in 5 daily fractions

06

What researchers measure

Primary outcomes

  1. Number of Patients With Any Toxicity Related to the Radiation Treatment

    Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.

    Time frame: during treatment, 2 and 6 weeks post treatment and then every 6 months for up to 2 years

Secondary outcomes

  1. Number of Participants With Ipsilateral Breast Local Recurrence

    Time frame: annually for 2 years post treatment

07

Results

Posted Aug 25, 2020

Participant flow

Participant flow — Overall Study
MilestoneAccuboost APBI
Started40
Completed40
Not completed0

Outcome measures

PrimaryNumber of Patients With Any Toxicity Related to the Radiation Treatment

Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.

Time frame:
during treatment, 2 and 6 weeks post treatment and then every 6 months for up to 2 years
Reported as:
Count of participants · Participants
Number of Patients With Any Toxicity Related to the Radiation Treatment
ParticipantsAccuboost APBI
Number of Patients With Any Toxicity Related to the Radiation Treatment40
SecondaryNumber of Participants With Ipsilateral Breast Local Recurrence
Time frame:
annually for 2 years post treatment
Reported as:
Count of participants · Participants
Number of Participants With Ipsilateral Breast Local Recurrence
ParticipantsAccuboost APBI
Number of Participants With Ipsilateral Breast Local Recurrence2

Adverse events

Collected over Data was collected from signing of ICF until 5 years post treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Accuboost APBI—0/40 (0%)36/40 (90%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventAccuboost APBI
Acute Skin ReactionSkin and subcutaneous tissue disorders32/40
DiscomfortGeneral disorders27/40
FatigueGeneral disorders19/40
TelangiectasiaSkin and subcutaneous tissue disorders13/40
Breast Volume/HypoplasiaReproductive system and breast disorders11/40
Skin Induration/FibrosisSkin and subcutaneous tissue disorders8/40
HyperpigmentationSkin and subcutaneous tissue disorders7/40
Breast PainReproductive system and breast disorders5/40
Fibrosis-cosmesisMusculoskeletal and connective tissue disorders3/40
Skin AtrophySkin and subcutaneous tissue disorders3/40

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Accuboost APBI
<=18 years0
Between 18 and 65 years14
>=65 years26
Age, Continuous
Age, Continuous(years)Accuboost APBI
Mean67.45 (50 to 89)
Sex: Female, Male
Sex: Female, Male(Participants)Accuboost APBI
Female40
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Accuboost APBI
Hispanic or Latino0
Not Hispanic or Latino0
Unknown or Not Reported40
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Accuboost APBI
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White39
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Accuboost APBI
United States40
08

Study locations

3 sites
  • UCSD Moores Cancer Center
    La Jolla, California 92093, United States
  • Watson Cancer Center
    Lakeland, Florida 33805, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01961531
Lead sponsor
Brown University
Collaborators
Watson Clinic Cancer Center, Cancer Treatment Centers of America, University of California, San Diego
Responsible party
Sponsor
First posted
Oct 11, 2013
Start date
Jul 24, 2014
Primary completion
Oct 26, 2016
Completion
Nov 30, 2021
Results posted
Aug 25, 2020
Last update
Mar 4, 2022

Study contacts

Jaroslaw Hepel, M.D.
principal investigator · Brown University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion